Journal Mobile Options
Table of Contents
Vol. 54, No. 6, 2008
Issue release date: October 2008
Section title: Experimental Chemotherapy
Chemotherapy 2008;54:438–446
(DOI:10.1159/000158663)

In vitro and in vivo Study of Cell Growth Inhibition of Simvastatin on Chronic Myelogenous Leukemia Cells

Yang Y.-C. · Huang W.-F. · Chuan L.-M. · Xiao D.-W. · Zeng Y.-L. · Zhou D.-A. · Xu G.-Q. · Liu W. · Huang B. · Hu Q.
aClinical Laboratory Department, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, and bLaboratory Medicine Department, Chongqing Medical University, Chongqing, China

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Experimental Chemotherapy

Received: 3/10/2008
Accepted: 6/22/2008
Published online: 9/30/2008

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE

Abstract

Background: Statins, a family of 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase inhibitors, are being investigated for the therapy and prevention of cancers. Here we aimed to investigate the effects of simvastatin on chronic myelogenous leukemia (CML) cells in vitro and in vivo, and to elucidate the mechanisms. Methods: Cell proliferation and cell cycle were measured after K562 cells were incubated with simvastatin, and differentially expressed genes were determined by oligonucleotide microarray. Changes of 2 genes obtained by oligonucleotide microarray were validated by real-time RT-PCR, and immunohistochemistry was performed to determine expression of proliferating cell nuclear antigen (PCNA). Finally, a xenograft tumor model was constructed to evaluate the effects of simvastatin in vivo. Results: Simvastatin could inhibit K562 cell proliferation, and the inhibition rate was approximately 30% after treatment with 20 µmol/l simvastatin for 48 h. Cell cycle was arrested in G1 phase, as shown by flow cytometry results. Fifteen downregulated, 9 upregulated cell cycle-related genes and decreased PCNA protein were observed in the presence of simvastatin. Furthermore, simvastatin exhibited impairment of xenograft tumor growth in nude mice and also blocked cell cycle in G1 phase. Conclusion: Simvastatin can inhibit CML cell proliferation in vitro and in vivo, and its mechanisms might be involved in cell cycle regulation.


  

Author Contacts

Wen-Fang Huang
Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital
Chengdu (China)
Tel. +86 28 8739 4056, Fax +86 28 8739 4056
E-Mail huangwf2002@21cn.com

  

Article Information

Received: March 10, 2008
Accepted after revision: June 22, 2008
Published online: September 30, 2008
Number of Print Pages : 9
Number of Figures : 3, Number of Tables : 4, Number of References : 31

  

Publication Details

Chemotherapy (International Journal of Experimental and Clinical Chemotherapy)

Vol. 54, No. 6, Year 2008 (Cover Date: October 2008)

Journal Editor: Sörgel F. (Nürnberg-Heroldsberg)
ISSN: 0009–3157 (Print), eISSN: 1421–9794 (Online)

For additional information: http://www.karger.com/CHE


Article / Publication Details

First-Page Preview
Abstract of Experimental Chemotherapy

Received: 3/10/2008
Accepted: 6/22/2008
Published online: 9/30/2008

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.